Trial Search Results
Detection of Graft Versus Host Disease With [18F]F-AraG
This is imaging study to determine utility of in vivo imaging with [18F]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD.
Stanford is currently accepting patients for this trial.
CellSight Technologies, Inc.
Collaborator: Stanford University
- Drug: [18F]F-Ara-G
1. Must be 21 years of age or older.
2. Must understand and voluntarily have signed an Informed Consent after its contents
have been fully explained.
1. For patients highly suspected to have aGVHD and requiring systemic therapy,
informed consent should be signed after biopsy taken to support clinical
2. For patients at high risk for developing aGVHD, informed consent should be signed
prior to transplant.
3. For healthy volunteers only: Must have no known medical problems that would make
undergoing the scan hazardous to the health of the patient or interfere with the
results. In particular subjects should not have any cardiac or immunological disorders
as these would likely affect the scan results. Subjects should have had a full
physical exam within 6 months of the study. If healthy volunteers have not had a full
medical exam within 6 months of the study, one of the nuclear medicine physicians will
conduct the medical exam prior to any study procedures.
4. For patients highly suspected to have aGVHD and requiring systemic therapy only:
Taking steroid treatment for suspected aGVHD for 3 days or less.
5. For patients at high risk for developing aGVHD only: Recipients of myeloablative or
reduced intensity allogeneic transplants using either bone marrow or peripheral blood
stem cells from HLA-matched or HLA-mismatched related or unrelated donors (protocols
9142, 9022, 9924) who have not yet been placed on any therapy for acute GVHD.
1. Pregnant or nursing
2. Individuals with known or suspected substance abuse, obtained by self-reporting.
3. Uncontrolled infection
4. Relapsed/persistent malignancy
5. Currently receiving immunotherapy
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study